Skip to main content

27-10-2010 | Diabetes | Article

Ranibizumab effective for improving visual acuity in DME patients


Free abstract

MedWire News: Ranibizumab is effective for improving best corrected visual acuity (BCVA) and central retinal thickness (CRT) and is well tolerated in patients with diabetic macular edema (DME), show results from the RESOLVE study.

The Ranibizumab in Diabetic Macular Edema (RESOLVE) study included 151 patients with Type 1 or 2 diabetes and DME who were assigned in a 1:1:1 fashion to three monthly injections with ranibizumab 0.3 or 0.5 mg or sham treatment. The patients had a CRT of greater than or equal to 300 µm and a BCVA of 73-39 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale.

After the three injections, treatment could be stopped or re-initiated with an opportunity for rescue laser photocoagulation. The participants were followed up for 12 months.

Sebastian Wolf (University of Bern, Switzerland) and colleagues report that BCVA had improved by 10.3 letters from baseline in the pooled ranibizumab group compared with a reduction of 1.4 letters in the sham treatment group, a statistically significant difference.

CRT was also significantly reduced at 12 months in the pooled ranibizumab group compared with the sham group, by 194.2 versus 48.4 µm.

BCVA improved by 10 letters or more in 60.8% of the ranibizumab versus 18.4% of the sham treatment group.

Ranibizumab was well tolerated and the rates of adverse events did not differ significantly between the two groups.

"This study appears promising for the use of ranibizumab in the treatment of DME, with a good safety profile," commented Pedro Romero-Aroca (Universitat Rovira i Virgili, Reus, Spain) the author of an accompanying editorial.

"Anti-Vascular endothelial growth factor (VEGF) drugs seem to be a promising alternative for the treatment of DME, but it is still necessary to define the dose and the time between injections."

He concluded: "A clinical trial directly comparing the efficacy and safety of anti-VEGF treatment with conventional laser therapy is warranted."

The results of this study are published in the journal Diabetes Care.

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Helen Albert